• Gregg S Larson, Beth R Baseler, Marie L Hoover, Jerome F Pierson, Jemee K Tegli, Melvin P Johnson, Kieh Mark W S MWS Liberia-US Clinical Trials Partnership Program, Partnership for Research on Ebola Virus in Liberia (PREVAIL), Monrovia, Liberia., Laura A McNay, and Wissedi Sio Njoh.
• Coordinating Centers for Biometric Research, Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, Minnesota.
• Am. J. Trop. Med. Hyg. 2017 Jul 1; 97 (1): 10-15.

AbstractClinical trials are challenging endeavors. Planning and implementing an investigational vaccine trial in Liberia, in the midst of an Ebola virus disease (EVD) epidemic that World Health Organization classified a public health emergency of international concern, presented extraordinary challenges. Normally, years of preparation and a litany of tasks lay the groundwork for a successful, randomized, blinded, placebo-controlled trial focused on safety and efficacy. Difficult research settings, unpredictable events, and other unique circumstances can add complexity. The setting in Liberia was especially problematic due to an infrastructure still badly damaged following a lengthy civil war and a very fragile health-care system that was further devastated by the EVD outbreak. The Partnership for Research on Vaccines in Liberia I EVD vaccine trial was planned and implemented in less than 3 months by a Liberian and U.S. research partnership, and its Phase II substudy was fully enrolled 3 months later. Contrasting conventional wisdom with trial outcomes offers an opportunity to compare early assumptions, barriers encountered, and adaptive strategies used, with end results. Understanding what was learned can inform future trial responses when disease outbreaks, especially in resource-poor locations with minimal infrastructure, pose a significant threat to public health.

21 keywords...

hide…